Abstract
Introduction and aims: In LIBERTY 1&2, once-daily relugolix combination therapy (Relugolix-CT; 40mg relugolix, estradiol 1mg, norethindrone acetate 0.5mg) improved uterine fibroid (UF)-associated heavy menstrual bleeding (HMB) versus placebo, was well tolerated, with preservation of bone mineral density (BMD) through 24 weeks. In LIBERTY LTE, MBL reduction was sustained with no new safety signals and BMD maintenance through 52 weeks. A descriptive subgroup analysis of European vs overall population is reported.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European journal of obstetrics, gynecology, and reproductive biology
Paper Title
Journal
Date
